Dr. Marni C. Wiseman
Section Head and Program Director, Section of Dermatology, Department of Medicine, University of Manitoba
Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001. In addition to her responsibilities as an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba, Dr. Wiseman spends most of her days at her Private Medical Practice as the Medical Director of SKiNWISE DERMATOLOGY.
Dr. Wiseman’s areas of clinical and research interest include psoriasis, atopic dermatitis, hidradenitis suppuritiva, acne, and aesthetic dermatology. She is a Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials.
Dr. Wiseman is a frequent supervisor and mentor for medical students and residents. She is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy.
Dr. Wiseman’s community commitments are extensive and include involvement with the Canadian Dermatology Association Sun Awareness program. She is an editor of the Journal of Cutaneous Medicine and Surgery, and was the chair of the Skin Cancer Disease Site Group at CancerCare Manitoba for 15 years. Dr. Wiseman holds regular outreach skin cancer screening clinics in rural locations in Manitoba, has been featured in many news stories, and regularly presents at meetings and congresses nationally and internationally.
NOV 3 (Fri)
Unmet Needs in Atopic Dermatitis: Towards a Mechanistic Understanding
- Describe the burden of uncontrolled atopic dermatitis in different patient populations
- Summarise recent translational discovery underlying itch, and the pathophysiology and phenotypes of AD
There are unmet needs in the management of atopic dermatitis (AD), especially in underserved areas. Itch is the most universal symptom in patients with AD and is typically the most burdensome symptom. When asked about the frequency of itch in 110 patients with AD in Canada surveyed by CSPA and Eczema Quebec, over 70% mentioned that they experienced itch everyday in the past week. With recent translational discoveries, there have been substantial advances in the understanding of the phenotypes of AD, the sensation of itch and its molecular pathways from skin to brain. This Open Session will review the burden of uncontrolled AD in different patient populations, the molecular mechanisms underlying the pathophysiology of AD and the sensation of itch.